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Available online 1 November 2014AbstractAims: Stereotactic ablative body radiotherapy (SABR) is a non-invasive treatment option for inoperable patients or patients with irresectable
liver tumors. Outcome and toxicity were evaluated retrospectively in this single-institution patient cohort.
Patients and methods: Between 2010 and 2014, 39 lesions were irradiated in 33 consecutive patients (18 male, 15 female, median age of 68
years). All the lesions were liver metastases (n ¼ 34) or primary hepatocellular carcinomas (n ¼ 5). The patients had undergone four-
dimensional respiration-correlated PET-CT for treatment simulation to capture tumor motion. We analyzed local control with a focus
on CT-based response at three months, one year and two years after treatment, looking at overall survival and the progression pattern.
Results: All patients were treated with hypofractionated image-guided stereotactic radiotherapy. The equivalent dose in 2 Gy fractions var-
ied from 62.5 Gy to 150 Gy, delivered in 3e10 fractions (median dose 93.8 Gy, alpha/beta ¼ 10). The CT-based regression pattern three
months after radiotherapy revealed partial regression in 72.7% of patients with a complete remission in 27.3% of the cases. The site of first
progression was predominantly distant. One- and two-year overall survival rates were 85.4% and 68.8%, respectively. No toxicity of grade 2
or higher according to the NCI Common Terminology Criteria for Adverse Events v4.0 was observed.
Conclusion: SABR is a safe and efficient treatment for selected inoperable patients or irresectable tumors of the liver. Future studies should
combine SABR with systemic treatment acting in synergy with radiation, such as immunological interventions or hypoxic cell radiosensi-
tizers to prevent distant relapse.
 2014 Elsevier Ltd. All rights reserved.
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2e4Introduction
Hepatocellular carcinoma (HCC) and hepatic metastatic
disease are significant clinical problems.1 With the intro-
duction of new chemotherapeutic drugs, a paradigm shift
in criteria for surgical resection and techniques like portal
vein embolization and repeat resection, the five-year sur-
vival rates for patients with colorectal liver metastasesthor. Tel.: þ31 88 445 5666; fax: þ31 88 445 5667.
ien.vandevoorde@maastro.nl (L. Van De Voorde).
16/j.ejso.2014.10.053
lsevier Ltd. All rights reserved.have doubled, from 30% to 60%. Unfortunately, the ma-
jority of patients with liver metastases are not surgical can-
didates because of tumor size, location, multifocality or
inadequate hepatic reserve. For such patients, stereotactic
ablative body radiotherapy (SABR) may be considered as
an alternative treatment.5,6 SABR is a high-precision
conformal external beam radiation that enables the delivery
of large doses of radiation to tumors with reduced margins
and steep dose gradients outside the target, thereby mini-
mizing doses to surrounding normal tissues. It is the only
250 L. Van De Voorde et al. / EJSO 41 (2015) 249e256truly non-invasive approach, combining high efficacy with
minimal side effects in the oligometastatic situation. It
has also emerged as a relatively new treatment for patients
with HCC who are unfit for surgical resection or ablation.
In addition, SABR is studied as a bridge to orthotopic liver
transplantation for patients with HCC. HCC is known as a
radiosensitive tumor and available data show a sustained tu-
mor response with radiotherapy.7e9
In this study, we investigated a cohort of patients with
HCC or oligometastatic liver tumors who were treated
with SABR at the MAASTRO Clinic. This review was per-
formed to report treatment response outcomes at three
months, local control rate and progression pattern. In addi-
tion, we hypothesized that using four-dimensional positron-
emission-computed-tomography (4D-PET/CT)-based free
breathing SABR on the liver with a higher radiotherapy
dose would result in improved local control.9
Patients and methodsPatient populationAfter receiving institutional review board approval, we
reviewed the records of 33 patients who had been treated
at the MAASTRO Clinic with SABR for the liver. All the
patients were required to have had a complete staging eval-
uation with history, physical exam, baseline liver function
test and full-body imaging with positron emission tomogra-
phy. Magnetic resonance imaging (MRI) or triple-phase
contrast-enhanced computed tomography (CT) was per-
formed to provide anatomical details of liver disease. We
did not exclude patients with extrahepatic disease as long
as it was amenable to other treatment (local or chemo-
therapy). Pathological confirmation of liver lesions prior
to treatment was not required unless it was the first presen-
tation of metastatic disease. The decision to treat patients
with SABR was made by the multidisciplinary tumor board
in the presence of at least one dedicated hepatobiliary
surgeon.Radiotherapy techniquePatients were immobilized in a supine position by the
breast board bilateral arm support system and the knee and
feet fixation system. The MAASTRO Clinic decided not to
use liver fiducial implants to guarantee patient comfort and
non-invasiveness. Because the liver continuously moves as
the patient breathes, we used 4D-PET/CT for treatment plan-
ning. The advantage of the 4D-PET/CT technique is that pa-
tients can freely breathe during the radiation sessions. All
patients received iodinated oral (Telebrix Gastro, 25 ml)
and intravenous contrast (150 ml Xenetix 300, Guerbet,
The Netherlands) for 15 min and 60 s, respectively, before
scanning. If available, magnetic resonance images were
used for accurate tumor delineation. Delineation was done
according to the current concepts of volume determinationas outlined in the International Commission on Radiation
Units and Measurements (ICRU) Report 83. Target defini-
tion was performed by contouring the gross tumor volume
(GTV) based on contrast-enhanced CT and fluorodeoxyglu-
cose (FDG) uptake. The GTV was considered to be identical
to clinical target volume. Clinical target volume was conse-
quently modified to create an internal target volume, ac-
counting for tumor movement using the 4D-PET/CT image
data. The planning target volume (PTV) was defined by add-
ing a 1 cm isotropic margin for set-up inaccuracy and patient
movement. Normal tissues including heart, esophagus,
lungs, ribs, skin, spinal cord, stomach, small and large bowel,
duodenum, kidneys and liver were defined as applicable.
Plans were designed using the Eclipse Treatment Plan-
ning System (Varian Medical Systems, Palo Alto, CA)
and five to seven rotational intensity modulated beams or
Volumetric Modulated Arc Therapy (VMAT/Rapidarc). A
prescription isodose surface that covered 95% of the PTV
was chosen (Fig. 1). The number of fractions and total
radiotherapy dose were adapted to the risk of toxicity to
the normal adjacent organs. When treated with a schedule
of three fractions of 20 Gy, the interval between two ses-
sions should be more than 40 h, but total treatment time
was restricted to eight days. In a schedule of eight fractions
of 7.5 Gy, radiotherapy was given every other day. When
treated with 5 Gy per fraction, a patient can be irradiated
on a daily basis. Before each treatment, a cone beam CT
(CBCT) scan was made for accurate patient set-up. The
CBCTwas registered to the planning CT using an algorithm
based on mutual information. For dosimetric accuracy, a
complete three-dimensional (3D) cone beam dose verifica-
tion procedure was performed (Fig. 2).10Follow-up and toxicityFollow-up consisted of imaging with either contrast-
enhanced spiral CT or contrast-enhanced dynamic MRI of
the treated area. In addition, we evaluated clinical examina-
tion and liver function tests three months after completing
SABR. Thereafter, we collected patient imaging studies at
three-to six-month intervals. Tumor assessment was
measured according to the modified Response Evaluation
Criteria in Solid Tumors (RECIST) criteria version 1.1.11
Toxicity was scored using the NCI Common Terminology
Criteria for Adverse Events (CTCAE) version 4.0.12 Any
toxicity that occurred within three months after the start of
SABR and that could theoretically be linked to the treatment
was considered acute. After three months, toxicity was
considered to be late. All patients were prescribed proton
pump inhibitors to reduce the risk of luminal gastrointestinal
toxicity until at least three months after the treatment.StatisticsWe performed an analysis with a follow-up update in
July 2014. The main study endpoints were local control
Figure 1. Respiratory-Correlated PET-CTwith peroral and intravenous contrast used for tumor delineation (upper) and RapidArc treatment planning (lower).
251L. Van De Voorde et al. / EJSO 41 (2015) 249e256and overall survival, estimated using methods developed by
Kaplan and Meier. Survival curves were compared using
the log-rank test. Local failure was defined per modified
RECIST criteria for assessing tumor diameter and viable
tumor tissue. Lesions that developed outside the liverFigure 2. 3D in vivo dosimetry using megavoltage cone beam (left), gamma eval
tribution (middle) and gamma dose volume histogram (right).were scored as distant progression. Comparison between
subgroups was calculated with Pearson’s chi-squared test.
Survival and control times were calculated from the start
of SABR. We hypothesized that local control is better
when lesions are irradiated with higher radiotherapy doses.uation of the comparison between the planned and reconstructed dose dis-
252 L. Van De Voorde et al. / EJSO 41 (2015) 249e256We tested this hypothesis with the ManneWhitney U test,
comparing two dose groups based on a median split of
equivalent dose in 2 Gy fractions (EQD2).
ResultsPatientsFrom May 2010 to May 2014, 33 patients with 39 liver
lesions were treated with SABR in the MAASTRO Clinic’s
Radiotherapy Department. Patient and tumor characteristics
are listed in Table 1. Five patients had HCC with limited
hepatic reserve, dictating a non-surgical approach.
Twenty-eight patients had only one metastatic site, four pa-
tients were treated for two lesions and only one patient had
three treated liver metastases. Table 1 shows that liver
segment VIII was most often presented for stereotactic
treatment given the proximity of the main intrahepaticTable 1
Patient clinical data.
Characteristic Value (%)
Total number of patients 33





























Below 100 Gy 17 (51.5)





Dosimetric value of the liver
Mean dose (Gy) 14
Mean volume healthy liver (ml) 1562.9vessels. Different fractionation schedules were used, de-
pending on the location of the nearby organs at risk. If
the tumor was located near the stomach or duodenal wall,
we gave priority to the at-risk organs and increased the
number of fractions. EQD2 varied from 62.5 Gy to
150 Gy delivered in 3e10 fractions (median dose
93.8 Gy, alpha/beta ¼ 10). No patients were lost to
follow-up and all the patients were evaluated for local con-
trol. One-third of patients (n ¼ 11) received systemic ther-
apy within six months before and/or after treatment with
SABR. Thirty percent of patients (n ¼ 10) had undergone
liver surgery (hemihepatectomy or metastasectomy) in the
past. Only one patient experienced multiple sessions of ra-
diofrequency ablation to attempt to control his hepatocellu-
lar carcinoma.Treatment outcomesThe CT-based regression pattern three months after
radiotherapy revealed regression in 72.7% of patients
with a complete remission in 27.3% of the cases (Fig. 3).
The site of the first progression was predominantly distant.
In 18.2% of patients, the progression pattern was distant
only and in an equal percentage the pattern was distant
and outfield hepatogenous. We found no progression at
the treated site. About 42.4% of patients remained free
from progression at the last follow-up (mean follow-up
time was 21 months). For hepatocellular carcinoma, all
five patients showed response on CT three months after
SABR with 60% of them having partial response and
40% having a complete remission. Two of them (40%)
developed a new lesion in the liver suspect for hepatocellu-
lar carcinoma in the course of time. No patient with hepa-
tocellular carcinoma developed in-field tumor relapse
which can perhaps be explained by our high institutional
treatment dose. Regarding patients with colorectal liver me-
tastases, 24% patients (n ¼ 4) were seen with complete
remission, 41% patients with partial (n ¼ 7) and 35%
(n ¼ 6) patients with stable disease. In the group of patients
with non colorectal metastases (n ¼ 11), the distribution of
response was more of less the same with 27% complete
response (n ¼ 3), 45% partial response (n ¼ 5) and three
patients or 27% stable disease. There was no statistically
significant difference in CT-based response between the
different subgroups: colorectal, non colorectal metastases
and hepatocellular carcinoma.
The one- and two-year overall survival rates were 85.4%
and 68.8%, for the whole group. The median survival was
29 months (Fig. 4). We report a median survival rate for pa-
tients with non colorectal metastases, colorectal metastases
and hepatocellular carcinoma of 29, 25 and 20 months
respectively.
Regarding the dose-treatment effect, we recorded a
significantly higher rate of complete remission with an
EQD2  100 Gy ( p value ¼ 0.017). The estimated median
survival time for the high-dose radiotherapy group was 32
Figure 3. Four-phase liver CT-scan in a patient with a history of right hemihepatectomy presenting with a hypodense unsharp defined lesion in liver segment
IVA (left). Portal venous phase imaging after SABR shows significant reduction of lesion diameter with perfusion defects associated with postradiotherapy
effects (right).
253L. Van De Voorde et al. / EJSO 41 (2015) 249e256months, compared with 25 months for the group that
received a dose below 100 Gy. Overall comparison of the
difference in survival distribution between these two sub-
groups was not significant ( p ¼ 0.109; Fig. 4). Further-
more, PTV was significantly smaller for patients with
complete or partial remission (average volume of 130 and
277 ml, respectively; p ¼ 0.026). Other than having a
higher radiation dose and lesser volume of the irradiated
target volume, we could identify no singular unifying char-
acteristic for predicting the likelihood of SABR failure in
the future.Treatment-related toxicityNo patient experienced acute toxicity equal to or above
grade 3. When patients were asked about the side effects of
treatment, the most commonly mentioned was fatigue
(n ¼ 11, 33%). If needed we prescribed anti-emetics to use
before treatment but only 24% of patients (n ¼ 8) experi-
enced grade 1 nausea. One patient who was treated with a
high dose (3  20 Gy) had a rise in temperature at the day
of treatment and experienced flu-like symptoms after eachFigure 4. KaplaneMeier estimates of overall survival (lesession. Two patients presented with abdominal cramps
and diarrhea, but these symptoms were self-limiting and
did not require any medical intervention. Only one patient
had skin toxicity with grade 1 itchy erythema; the patient
had fully recovered three weeks after treatment. Regarding
late toxicity, one patient developed a cough three months af-
ter SABR with radiographic consolidation of the right lung
base. Corticosteroids were started based on a tentative diag-
nosis of radiation pneumonitis and the symptoms resolved
over the course of one month. We found no radiation-
induced liver disease (RILD). There was no marked differ-
ence in reported toxicity between patients with liver oligo-
metastases and primary hepatocellular carcinoma. We
notice that only one patient treated for hepatocellular carci-
noma with SABR had underlying liver cirrhosis Child-
Pugh A.
Discussion
Liver resection both prolongs survival and offers the
chance for cure for selected patients with oligometastates
of the liver or hepatocellular carcinoma.3,13,14ft) among patients stratified by EQD2 dose (right).
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able at presentation. Risk scoring systems (e.g. Fong score)
are of limited clinical utility and the definition of ‘unresect-
able’ is often based on the aggressiveness of the liver
surgeon.4,15e17 Injudicious and excessive use of chemo-
therapy and biologics to convert liver-limited but unresect-
able disease can cause irreversible liver parenchymal
damage that leads to increased postoperative morbidity
and mortality.18 Furthermore, multiple studies have shown
that the results of repeat hepatectomy for liver recurrent
disease are comparable to the first resection in terms of
overall survival, but often at the cost of higher perioperative
mortality and morbidity.
New and innovative treatment strategies to ablate liver
tumors are rapidly developing (e.g., microwave, nano-
knife or irreversible electroporation, intra-arterial brachy-
therapy). These treatments have limitations and
advantages, but all of them are associated with a minimal
invasive component. Stereotactic radiotherapy of the liver
has emerged as a valuable alternative primary or comple-
mentary treatment strategy for liver oligometastatic dis-
ease or primary HCC, especially when vascular
proximity or multinodularity is present.19e22 The advan-
tage of SABR is its true non-invasive aspect and the inde-
pendence of tumor location or risk of biliary injury. The
ability to give large doses in fractions creates the possibil-
ity of additional biological effects resulting from endothe-
lial cell damage and/or enhanced tumor immunity.23 Until
now, no large prospective studies or randomized studies
have compared SABR with surgery and other treatment
modalities.
In this study, we analyzed a prospective series of patients
treated by SABR liver after evaluation by a university-
hospital-based multidisciplinary team. The results of the
analysis are challenging since our patient population was
characterized by old age and frailty, with or without pre-
existing liver disease. This study also has some limitations
since it is a retrospective investigation retrieved from a real-
life university hospital clinical environment. We report a
complete remission in 27% of patients but define local con-
trol as complete or partial remission. This percentage of
complete remission could be an underestimation because
of inaccurate radiologic response interpretation especially
just after implementing this technique. The administration
of ablative radiation doses can result in specific changes
to both the tumor and the healthy hepatic parenchyma mak-
ing the assessment of local changes after SABR often diffi-
cult. As SABR becomes more widely practiced there is a
need for uniform guidelines in radiologic assessment of
these treated lesions. We have to communicate with our
radiologist that tumor size and shape are not the main
criteria to differentiate between postradiotherapy effects
and tumor recurrence. Reduction in viable tumor volume
is considered as the optimal method for assessing local
response to SABR. Furthermore, the CT based response af-
ter SABR can shift with longer follow-up but the durationof each radiologic stage is individually different. In future,
it is mandatory to standardize and simplify our evaluation
criteria. This way we can benefit of a better understanding
of the effectiveness of this new treatment modality and
allow better reproducibility of available imaging exams.
Limited data, evaluating the role of diffusion-weighted
magnetic resonance imaging (DW-MRI) in treatment
response after SABR liver, show that apparent diffusion co-
efficient (ADC) increases early in response to therapy.24,25
Diffusion weighted imaging (DWI) is a technique that
might hold promise as an early biomarker for sustained
response to SABR especially for liver oligometastases in
the non-cirrhotic liver.26 We encourage future multi-
institutional trials to incorporate imaging biomarkers in
SABR liver protocol design with improvement and stan-
dardization of the DWI technique and measurement
method. This will require improved collaborations between
imaging scientists radiologists, hepatobiliary surgeons and
radiation oncologists. Until now, we recommend using
the modified RECIST criteria proposed by the American
Association for the Study of Liver Diseases (AASLD) for
assessment after SABR of the liver. This way the percent-
age of tumor necrosis is more important than change in tu-
mor diameter.11 Another limitation in our study is that the
small number of patients in the different subgroups (colo-
rectal, non colorectal and hepatocellular carcinoma) made
all-encompassing statements about outcome differences
difficult because of the limited statistical power. Toxicity
is mild but analysis is terse since this was not prospectively
scored. Higher biologic radiation dose and smaller treat-
ment volume seem to have prognostic value in improve-
ment of local control.
Our treatment results compare favorably with other pub-
lished data about SABR of the liver.9,27 Local control was
excellent with no recurrence at the treated liver site.
Although intuitively appealing, we note that when surgery
provides good local control, the local control advantage
provided by other non-invasive treatment modalities may
not lead to a statistically significant survival advantage if
the competing risk of distant metastases of the treated pop-
ulation is very high. Until now, the recommendations of the
multidisciplinary tumor board have resulted in an unbal-
anced distribution of patients based on a number of factors
that would prima facie suggest surgical resection. Our insti-
tution chose to maintain a non-invasive strategy, in that
there were no fiducials implanted to guide radiotherapy.
Our outcome data show that our high-precision radio-
therapy margin recipe is definitely adequate.
SABR is a safe and non-invasive procedure provided
that high-quality treatment planning is used and that con-
straints for the organs at risk are respected. However,
caution must be taken when performing it on patients
who have been treated with bevacizumab less than six
weeks before radiotherapy. This anti-VEGFR monoclonal
antibody has been associated with an increased incidence
of bowel ulceration and perforation, both with and without
255L. Van De Voorde et al. / EJSO 41 (2015) 249e256radiotherapy. Blockage of vascularity in the bowels, result-
ing in hypoxia, necrosis and tissue breakdown, is probably
the main cause of this toxicity.28e32 Despite several clinical
factors like pre-existing liver dysfunction, prior therapy and
portal vein thrombosis, accurate prediction of RILD re-
mains a challenge. Adaptation of SABR that takes individ-
ual patients’ sensitivity into account is the goal of future
development.33 In addition, the use of hypoxic cell radio-
sensitizers can increase SABR’s therapeutic ratio by over-
coming potential hypoxic resistance. In this way, we
could create the possibility of re-irradiating a liver tumor
or using SABR as a salvage strategy in recurrent hepatocel-
lular carcinoma.34 Among the most promising preclinical
treatment approaches is combining SABR with immuno-
therapy: early data suggests that it causes synergistic and
‘abscopal’ effects in several tumor model systems.35
Conclusion
The management of liver metastases and primary hepa-
tocellular carcinoma requires a multidisciplinary approach
and the intention to treat on a case-by-case basis. Current
data do not support planning for surgical resection with
foreknowledge that residual disease will be left behind.36
Stereotactic radiotherapy of the liver has a firm role both
as an adjunct to surgical resection and in the management
of patients who are not surgical candidates. In our consec-
utive cohort of patients with liver-limited unresectable oli-
gometastases of the liver or primary hepatocellular
carcinoma, SABR provided excellent sustained local con-
trol. Combining 4D-PET/CT imaging with 3D cone beam
CT-based in vivo dosimetric verification resulted in a highly
tolerable, fast and accurate treatment. However, the ulti-
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